These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 9443710)

  • 1. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment.
    Heseltine PN; Goodkin K; Atkinson JH; Vitiello B; Rochon J; Heaton RK; Eaton EM; Wilkie FL; Sobel E; Brown SJ; Feaster D; Schneider L; Goldschmidts WL; Stover ES
    Arch Neurol; 1998 Jan; 55(1):41-51. PubMed ID: 9443710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of D-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment.
    Goodkin K; Vitiello B; Lyman WD; Asthana D; Atkinson JH; Heseltine PN; Molina R; Zheng W; Khamis I; Wilkie FL; Shapshak P
    J Neurovirol; 2006 Jun; 12(3):178-89. PubMed ID: 16877299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment.
    Nakasujja N; Miyahara S; Evans S; Lee A; Musisi S; Katabira E; Robertson K; Ronald A; Clifford DB; Sacktor N
    Neurology; 2013 Jan; 80(2):196-202. PubMed ID: 23269596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for cognitive impairment in HIV-1-infected persons with different risk behaviors.
    De Ronchi D; Faranca I; Berardi D; Scudellari P; Borderi M; Manfredi R; Fratiglioni L
    Arch Neurol; 2002 May; 59(5):812-8. PubMed ID: 12020265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. The Peptide T Neuropathy Study Group.
    Simpson DM; Dorfman D; Olney RK; McKinley G; Dobkin J; So Y; Berger J; Ferdon MB; Friedman B
    Neurology; 1996 Nov; 47(5):1254-9. PubMed ID: 8909439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide T for cognitive impairment.
    Smart T
    GMHC Treat Issues; 1995 Sep; 9(9):15. PubMed ID: 11362907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained cognitive decline in HIV infection: relationship to CD4+ cell count, plasma viremia and p24 antigenemia.
    Dal Pan GJ; Farzadegan H; Selnes O; Hoover DR; Miller EN; Skolasky RL; Nance-Sproson TE; McArthur JC
    J Neurovirol; 1998 Feb; 4(1):95-9. PubMed ID: 9531016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
    Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
    Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of early AIDS dementia in intravenous drug users: high versus low dose peptide T.
    Kosten TR; Rosen MI; McMahon TL; Bridge TP; O'Malley SS; Pearsall R; O'Connor PG
    Am J Drug Alcohol Abuse; 1997 Nov; 23(4):543-53. PubMed ID: 9366972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of efficacy of low dose oral interferon alfa in symptomatic HIV-1 infection: a randomised, double blind, placebo controlled trial.
    Katabira ET; Sewankambo NK; Mugerwa RD; Belsey EM; Mubiru FX; Othieno C; Kataaha P; Karam M; Youle M; Perriens JH; Lange JM
    Sex Transm Infect; 1998 Aug; 74(4):265-70. PubMed ID: 9924466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication.
    Vassallo M; Fabre R; Durant J; Lebrun-Frenay C; Joly H; Ticchioni M; DeSalvador F; Harvey-Langton A; Dunais B; Laffon M; Cottalorda J; Dellamonica P; Pradier C
    J Neurovirol; 2017 Apr; 23(2):216-225. PubMed ID: 27815816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment.
    Clifford DB; McArthur JC; Schifitto G; Kieburtz K; McDermott MP; Letendre S; Cohen BA; Marder K; Ellis RJ; Marra CM;
    Neurology; 2002 Nov; 59(10):1568-73. PubMed ID: 12451199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive performance after progression to AIDS: a longitudinal study from the Multicenter AIDS Cohort Study.
    Selnes OA; Galai N; Bacellar H; Miller EN; Becker JT; Wesch J; Van Gorp W; McArthur JC
    Neurology; 1995 Feb; 45(2):267-75. PubMed ID: 7854524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of the antioxidant OPC-14117 in HIV-associated cognitive impairment. The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders.
    Neurology; 1997 Jul; 49(1):142-6. PubMed ID: 9222182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals.
    Anderson AM; Lennox JL; Mulligan MM; Loring DW; Zetterberg H; Blennow K; Kessing C; Koneru R; Easley K; Tyor WR
    J Neurovirol; 2017 Feb; 23(1):106-112. PubMed ID: 27400930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide T not effective for cognitive impairment.
    Posit Aware; 1996; 7(1):5. PubMed ID: 11363121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low blood CD8+ T-lymphocytes and high circulating monocytes are predictors of HIV-1-associated progressive encephalopathy in children.
    Sánchez-Ramón S; Bellón JM; Resino S; Cantó-Nogués C; Gurbindo D; Ramos JT; Muñoz-Fernández MA
    Pediatrics; 2003 Feb; 111(2):E168-75. PubMed ID: 12563091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivastigmine for vascular cognitive impairment.
    Birks J; McGuinness B; Craig D
    Cochrane Database Syst Rev; 2013 May; (5):CD004744. PubMed ID: 23728651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.